Beam Therapeutics Net Income
| BEAM Stock | USD 27.92 0.30 1.09% |
As of the 3rd of February, Beam Therapeutics shows the risk adjusted performance of 0.038, and Mean Deviation of 3.4. Beam Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Beam Therapeutics jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Beam Therapeutics is priced correctly, providing market reflects its regular price of 27.92 per share. Given that Beam Therapeutics has jensen alpha of 0.1082, we suggest you to validate Beam Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.
Beam Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 33.7371 | Revenue | Earnings Share (4.41) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -339.1 M | -322.1 M | |
| Net Loss | -339.1 M | -356 M | |
| Net Loss | -234.2 M | -245.9 M | |
| Net Loss | (5.26) | (5.53) | |
| Net Income Per E B T | 0.90 | 0.80 |
Beam | Net Income | Build AI portfolio with Beam Stock |
Evaluating Beam Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Beam Therapeutics's fundamental strength.
Latest Beam Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Beam Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Beam Therapeutics financial statement analysis. It represents the amount of money remaining after all of Beam Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Beam Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Beam Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (376.74 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Beam Net Income Regression Statistics
| Arithmetic Mean | (134,599,285) | |
| Coefficient Of Variation | (109.74) | |
| Mean Deviation | 127,605,471 | |
| Median | (78,326,000) | |
| Standard Deviation | 147,706,078 | |
| Sample Variance | 21817.1T | |
| Range | 368M | |
| R-Value | (0.86) | |
| Mean Square Error | 5953.4T | |
| R-Squared | 0.74 | |
| Slope | (25,232,825) | |
| Total Sum of Squares | 349073.4T |
Beam Net Income History
Other Fundumenentals of Beam Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Beam Therapeutics Net Income component correlations
Beam Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Beam Therapeutics is extremely important. It helps to project a fair market value of Beam Stock properly, considering its historical fundamentals such as Net Income. Since Beam Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Beam Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Beam Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Beam diversify its offerings? Factors like these will boost the valuation of Beam Therapeutics. Projected growth potential of Beam fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Beam Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.41) | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Beam Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Beam Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Beam Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Beam Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Beam Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Beam Therapeutics.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in Beam Therapeutics on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding Beam Therapeutics or generate 0.0% return on investment in Beam Therapeutics over 90 days. Beam Therapeutics is related to or competes with Agios Pharm, Denali Therapeutics, Recursion Pharmaceuticals, Immunitybio, Arcus Biosciences, Cogent Biosciences, and Mineralys Therapeutics. Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from seriou... More
Beam Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Beam Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Beam Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.79 | |||
| Information Ratio | 0.029 | |||
| Maximum Drawdown | 31.78 | |||
| Value At Risk | (6.28) | |||
| Potential Upside | 8.12 |
Beam Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Beam Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Beam Therapeutics' standard deviation. In reality, there are many statistical measures that can use Beam Therapeutics historical prices to predict the future Beam Therapeutics' volatility.| Risk Adjusted Performance | 0.038 | |||
| Jensen Alpha | 0.1082 | |||
| Total Risk Alpha | (0.12) | |||
| Sortino Ratio | 0.0385 | |||
| Treynor Ratio | 0.1051 |
Beam Therapeutics February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.038 | |||
| Market Risk Adjusted Performance | 0.1151 | |||
| Mean Deviation | 3.4 | |||
| Semi Deviation | 3.66 | |||
| Downside Deviation | 3.79 | |||
| Coefficient Of Variation | 2491.96 | |||
| Standard Deviation | 5.02 | |||
| Variance | 25.23 | |||
| Information Ratio | 0.029 | |||
| Jensen Alpha | 0.1082 | |||
| Total Risk Alpha | (0.12) | |||
| Sortino Ratio | 0.0385 | |||
| Treynor Ratio | 0.1051 | |||
| Maximum Drawdown | 31.78 | |||
| Value At Risk | (6.28) | |||
| Potential Upside | 8.12 | |||
| Downside Variance | 14.37 | |||
| Semi Variance | 13.39 | |||
| Expected Short fall | (4.06) | |||
| Skewness | 1.63 | |||
| Kurtosis | 5.42 |
Beam Therapeutics Backtested Returns
Beam Therapeutics appears to be not too volatile, given 3 months investment horizon. Beam Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0867, which signifies that the company had a 0.0867 % return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for Beam Therapeutics, which you can use to evaluate the volatility of the firm. Please makes use of Beam Therapeutics' risk adjusted performance of 0.038, and Mean Deviation of 3.4 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Beam Therapeutics holds a performance score of 6. The firm shows a Beta (market volatility) of 1.82, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Beam Therapeutics will likely underperform. Please check Beam Therapeutics' sortino ratio, semi variance, and the relationship between the standard deviation and value at risk , to make a quick decision on whether Beam Therapeutics' price patterns will revert.
Auto-correlation | 0.49 |
Average predictability
Beam Therapeutics has average predictability. Overlapping area represents the amount of predictability between Beam Therapeutics time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Beam Therapeutics price movement. The serial correlation of 0.49 indicates that about 49.0% of current Beam Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.49 | |
| Spearman Rank Test | 0.52 | |
| Residual Average | 0.0 | |
| Price Variance | 5.94 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Beam Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Beam Therapeutics reported net income of (376.74 Million). This is 210.39% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 165.98% higher than that of the company.
Beam Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Beam Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Beam Therapeutics could also be used in its relative valuation, which is a method of valuing Beam Therapeutics by comparing valuation metrics of similar companies.Beam Therapeutics is currently under evaluation in net income category among its peers.
Beam Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Beam Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Beam Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Beam Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Beam Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Beam Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Beam Therapeutics' value.| Shares | Kynam Capital Management, Lp | 2025-06-30 | 2.4 M | Citadel Advisors Llc | 2025-06-30 | 2.3 M | Mwg Management Ltd. | 2025-06-30 | 2.3 M | Geode Capital Management, Llc | 2025-06-30 | 2.3 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 1.8 M | Casdin Capital, Llc | 2025-06-30 | 1.4 M | Redmile Group, Llc | 2025-06-30 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.3 M | Goldman Sachs Group Inc | 2025-06-30 | 1.3 M | Fmr Inc | 2025-06-30 | 13 M | Farallon Capital Management, L.l.c. | 2025-06-30 | 10 M |
Beam Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (13.08) % | ||||
| Current Valuation | 2.05 B | ||||
| Shares Outstanding | 101.47 M | ||||
| Shares Owned By Insiders | 1.23 % | ||||
| Shares Owned By Institutions | 98.77 % | ||||
| Number Of Shares Shorted | 20.04 M | ||||
| Price To Earning | 37.48 X | ||||
| Price To Book | 2.90 X | ||||
| Price To Sales | 50.32 X | ||||
| Revenue | 63.52 M | ||||
| Gross Profit | (356.09 M) | ||||
| EBITDA | (393.64 M) | ||||
| Net Income | (376.74 M) | ||||
| Cash And Equivalents | 1.09 B | ||||
| Cash Per Share | 15.90 X | ||||
| Total Debt | 161.43 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 4.64 X | ||||
| Book Value Per Share | 9.80 X | ||||
| Cash Flow From Operations | (347.25 M) | ||||
| Short Ratio | 11.03 X | ||||
| Earnings Per Share | (4.41) X | ||||
| Price To Earnings To Growth | (2.30) X | ||||
| Target Price | 47.21 | ||||
| Number Of Employees | 510 | ||||
| Beta | 2.07 | ||||
| Market Capitalization | 2.8 B | ||||
| Total Asset | 1.1 B | ||||
| Retained Earnings | (1.57 B) | ||||
| Working Capital | 696.08 M | ||||
| Current Asset | 2.89 B | ||||
| Current Liabilities | 706.6 M | ||||
| Net Asset | 1.1 B |
About Beam Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Beam Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Beam Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Beam Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Will Biotechnology sector continue expanding? Could Beam diversify its offerings? Factors like these will boost the valuation of Beam Therapeutics. Projected growth potential of Beam fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Beam Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.41) | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Beam Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Beam Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Beam Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.